CorMedix Inc

CRMD Healthcare Biotechnology

CorMedix Inc’s revenue for fiscal 2025 (year ended December 2025) was $311.7 million, up 617.0% from fiscal 2024. In the quarter to June 2026, revenue grew 156.5%, EPS grew 13.8% and free cash flow grew 185.9%, each against the same quarter a year earlier.

7.26 0.20 −2.68%
Market cap
$581.5M
P/E
3.0×
Fwd P/E
16.5×
Dividend yield
—
F-score
n/a
Altman Z
2.15
Beneish M
12.80
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 — — —

+8 more TTM periods

ROE
54.93% 65.59% 66.56% 75.08%
ROA
32.36% 37.51% 34.51% 39.23%
ROIC
38.84% 29.97% 23.38% 14.02%
Return on Tangible Assets
62.18% 69.49% 82.04% 124.77%
Average Days of Receivables
127.37 141.24 200.51 270.08
Free Cash Flow per Share
3.19 2.45 2.40 0.98
Free Cash Flow
250.42 194.71 172.79 74.42
Other line items

Show all line items

Columns are period end dates